Timothy G Geary

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 4 EPO patents. Top assignees: Mcgill University, Elanco US Inc., Ah USA 42 LLC. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy G Geary. Retrieved from https://idiyas.com/inventor/timothy-g-geary-dnpobhoq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 2.9

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Ste-Anne-de-Bellevue, CA (2014)
Quebec, CA (2013 - 2022)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12391991 - Markers to predict macrocyclic lactone drug resistance in, the causative agent of heartworm disease (2025-08-19),

2. 11414703 - Markers to predict macrocyclic lactone drug resistance in, the causative agent of heartworm disease (2022-08-16),

3. 10000811 - Markers to predict macrocyclic lactone drug resistance in dirofilaria immitis, the causative agent of heartworm disease (2018-06-19),

4. 8722332 - [object Object] (2014-05-13),

5. 8440633 - Anthelmintic combination (2013-05-14),

Title: Innovations by Timothy G Geary

Introduction

Timothy G Geary is a notable inventor based in California, recognized for his contributions to the field of veterinary medicine. He holds a total of 5 patents that focus on advancements in drug resistance prediction for heartworm disease.

Latest Patents

One of his latest patents involves markers to predict macrocyclic lactone drug resistance in the causative agent of heartworm disease. This patent discloses nucleic acid molecules from the genome of specific nematodes that contain single nucleotide polymorphisms related to reduced responsiveness to macrocyclic lactones. The species involved is the agent of heartworm in animals. Additionally, the patent outlines methods for determining the responsiveness of these nematodes to macrocyclic lactones, methods for selecting appropriate treatments for infected animals, and kits designed for assessing the responsiveness of these nematodes.

Career Highlights

Throughout his career, Timothy has worked with esteemed institutions such as McGill University and Elanco US Inc. His work has significantly impacted the understanding and treatment of heartworm disease in animals.

Collaborations

Timothy has collaborated with notable professionals in his field, including Roger K Prichard and Catherine Bourguinat. Their joint efforts have contributed to the advancements in veterinary pharmacology.

Conclusion

Timothy G Geary's innovative work in predicting drug resistance in heartworm disease showcases his dedication to improving animal health. His patents and collaborations reflect a commitment to advancing veterinary medicine through scientific research and innovation.

Profile summary based on public USPTO records.